Current Studies
Please click the trial name for more information.
Prostate Cancer
Prostate Cancer Treatment (NCT04844749)
Sponsor: Veracity
Summary: Treat mCRPC who have failed one androgen receptor targeting agent with an anti-microtubal oral agent (VERU-111).
Requirements:
- Participant must be ≥ 18 years of age
- Cancer must have spread to other parts of the body (metastatic disease)
- Prior treatment with at least one second-generation androgen-blocking therapy (i.e., abiraterone acetate or enzalutamide) that was unsuccessful
- PSA equal to or greater than 2.0 at screening
Exclusion:
- Bone scan with evidence of superscan or superscan phenomenon
- Currently taking warfarin
- Previous taxane chemo greater than 2 cycles
- Spinal cord compression
Compensation: Reimbursement Available
Prostate Cancer Treatment (NCT04122976)
Sponsor: Bayer
Summary: Darolutamide for patients with non-metastatic castration-resistant prostate cancer (nmCRPC) for whom a decision to treat with darolutamide has been made before enrollment.
Requirements:
- Participant must be ≥ 18 years of age
- Patients with castrate-resistant prostate cancer that has not spread throughout the body
Detection of Prostate Cancer Recurrence (NCT05249127)
Sponsor: Clarity Pharmaceuticals
Summary: Eligible participants will receive a single administration of 64Cu-SAR-bisPSMA followed by a positron emission tomography (PET)/computed tomography (CT) scan that is clinically suitable in the detection of prostate cancer and in detecting small lesions over time.
Requirements:
- Participant must be ≥ 18 years of age
- Rising PSA after definitive therapy (removal of prostate, radiation, brachytherapy)
- Cannot be taking medications for prostate cancer (androgen-deprivation therapy, antiandrogen, gonadotropin-releasing hormone, luteinizing hormone-releasing hormone agonist or antagonist)
Prostate Cancer Treatment (NCT05204927)
Sponsor: Curium
Summary: Patients with metastatic castrate-resistant prostate cancer who have failed androgen receptor therapy will be randomized to receive either novel PSMA radiopharmaceutical 177Lueticium or active control (enzalutamide or abiraterone) to assess overall survival.
Requirements:
- Participant must be ≥ 18 years of age
- Patients with prostate cancer that has spread to other parts of the body
- Previous treatment with abiraterone (Zytiga), enzalutamide (Xtandi), apalutamide (Erleada), or darolutamide (Nubeqa)
- No prior chemotherapy treatment
Prostate Cancer Treatment (NCT05288166)
Sponsor: Eli Lilly and Company
Summary: Phase 3 study to assess the safety and efficacy of adding abemaciclib to abiraterone (Xtandi) plus prednisone in patients with high-risk metastatic hormone-sensitive prostate cancer.
Requirements:
- Participant must be ≥ 18 years of age
- Presence of ≥4 bone metastases and/or ≥1 visceral metastases
- Cancer has spread to bones or other organs
- Participants must have initiated ADT (androgen deprivation therapy)
Prostate Cancer Treatment (NCT03850795)
Sponsor: Hinova Pharmaceuticals
Summary: Enrolling patients with metastatic castrate-resistant prostate cancer to evaluate the efficacy and safety of HINOVA drug against enzalutamide (Xtandi) in asymptomatic or mildly symptomatic patients with progressive metastatic prostate cancer.
Requirements:
- Participant must be ≥ 18 years of age
- Progressive disease characterized by rising PSA levels or cancer spreading to other parts of the body (metastasis)
Prostate Cancer Treatment (NCT04382898)
Sponsor: BioNTech SE
Summary: mRNA vaccine therapy that targets prostate cancer antigens with the antibody Cemiplimab. This study is for patients with a new diagnosis of prostate cancer who are going to have their prostate removed or for patients who have failed one line of androgen receptor therapy and cancer has spread to other parts of the body.
Requirements:
- Depends on cohort
Prostate Cancer Treatment (NCT04729114)
Sponsor: Propella Therapeutics, Inc.
Summary: This is a Phase 1/2a study of i.m. PRL-02 depot in patients with advanced prostate cancer.
Requirements:
- Depends on cohort
Prostate Cancer Treatment (NCT04821622)
Sponsor: Pfizer
Summary: The purpose of the study is to evaluate the safety and efficacy of talazoparib in combination with enzalutamide (Xtandi) compared with placebo in combination with enzalutamide (Xtandi) in participants.
Requirements:
- Participant must be ≥ 18 years of age
- Prostate cancer has spread to other parts of the body
- Patient must have a mutation in DNA Damage and Repair gene (DDR gene, i.e. ATM, ATR, BRACA, CDK, CHEK, etc.) to qualify
- Participant must not have received radiation
Prostate Cancer Treatment (NCT04843319)
Sponsor: Veru Inc.
Summary: Phase I trial of novel ADT Veru-100 in which patients receive 150mg one-time injection of Veru-100 and monitored with serial testosterone to evaluate the efficacy of castration.
Requirements:
- Participant must be ≥ 18 years of age
- Patient must be newly diagnosed with prostate cancer and have not yet received any therapy
Bladder Cancer
Bladder Cancer Treatment (NCT04640623)
Sponsor: Janssen Research & Development, LLC
Summary: A Phase 3 Study Evaluating the Efficacy and Safety of TAR-200 in Combination with Cetrelimab Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants with BCG-naïve High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC).
Requirements:
- 18 years or older
- Diagnosed with NMIBC
- Unresponsive to intravesical Bacillus Calmette-Guerin (BCG) therapy
- Ineligible for or have decided not to undergo radical cystectomy
Compensation: While qualified participants will not be paid for their participation, they will receive all study-related medications, visits, and tests at no cost.
Bladder Cancer Treatment (NCT03945162)
Sponsor: Theralase Technologies, Inc.
Summary: The goal of this study is to destroy tumor cells through photodynamic therapy in bladder cancer patients who have been through BCG.
Requirements:
- 18 years or older
- Bladder cancer has not spread throughout the body (metastasis)
- Patients must have had prior BCG therapy
- Must not have UTI
Bladder Cancer Treatment (NCT04919512)
Sponsor: Janssen, Inc.
Summary: This is a randomized, open-label, multicenter, Phase 2 clinical study of intravesical gemcitabine delivered via the TAR-200 drug delivery system in combination with neoadjuvant intravenous cetrelimab and neoadjuvant intravenous cetrelimab alone in participants with muscle-invasive urothelial carcinoma of the bladder who are scheduled for radical cystectomy and are ineligible for or refusing platinum-based neoadjuvant chemotherapy.
Requirements:
- Depends on cohort
Bladder Cancer Treatment (NCT05316155)
Sponsor: Janssen, Inc.
Summary: Phase 1 study of TAR-210 in participants with non-muscle invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) with specific FGFR mutations or fusions to evaluate anti-tumor activity
Requirements:
- 18 years or older
- Bladder cancer that has previously been treated but has now recurred
- Patients may or may not have had BCG therapy
Bladder Cancer Treatment (NCT03711032)
Sponsor: Merck Sharp & Dohme Corp.
Summary: A Phase 3 trial of BCG therapy with or without pembrolizumab (MK-3475) for high-risk non-muscle invasive bladder cancer that is either persistent or recurrent following BCG induction or naive to BCG.
Requirements:
- 18 years or older
- Must have undergone cystoscopy/TURBT
- History of muscle-invasive bladder cancer not permitted
Bladder Cancer Treatment (NCT04700124)
Sponsor: Merck Sharp & Dohme Corp.
Summary: A Phase 3 to evaluate pembrolizumab (MK-3475) versus neoadjuvant gemcitabine and cisplatin in participants with muscle-invasive bladder cancer (MIBC).
Requirements:
- 18 years or older
- Has NOT received any prior systemic treatment, chemoradiation, and/or radiation therapy treatment for MIBC
Bladder Cancer Treatment (NCT04919512)
Sponsor: Janssen, Inc.
Summary: Phase 2 Study of TAR-200 in Combination with Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible for or Refusing Platinum-Based Chemotherapy.
Requirements:
- 18 years or older
- Must not have received prior systemic chemotherapy, targeted small molecule therapy, or radiation therapy within 2 years prior
Biomarkers
Prostate Cancer Detection
Sponsor: Gregor Diagnostics
Summary: Semen Sample Collection and Processing for use in the Development of Prostate Cancer Diagnostic Tests
Requirements:
- Participant must be between 50 and 70 years of age
- Never received treatment for prostate cancer
- Healthy enough for sexual activity
Compensation: $100 gift card when you submit the sample
Biomarkers Study (NCT03662204 )
Sponsor: Exact Sciences
Summary: One-time blood collection to develop a molecular test to evaluate biomarkers in subjects with cancer.
Requirements:
- Patients with either a new cancer diagnosis that has not been treated, patients with clinical suspicion of cancer that has not been diagnosed, or patients with a recurrent cancer diagnosis or suspicion
- Patients with multiple cancer diagnoses are not permitted to enroll
Compensation: $50
Lung EpiCheck Biomarkers Development Study (NCT04968548)
Sponsor: Nucleix
Summary: One-time blood collection to develop a molecular test for early diagnosis of lung cancer from a blood sample that will be more sensitive and specific than existing tests.
Requirements:
- Patients that are either
- Nonsmokers age 20-80 that have no history of cancer in their lifetime
- Previous smokers with less than 20 pack years with no history of cancer in their lifetime
- Previous smokers with at least 20 pack years and no history of cancer in the past 5 years
- Active smokers with at least 20 pack years and no history of cancer in the past 5 years
Compensation: $25
Bladder Cancer Detection (NCT02700464)
Sponsor: Nucleix
Summary: Urine sample collection intended to be used with the Bladder EpiCheck Kit for the qualitative detection of DNA methylation patterns in human urine that are associated with transitional cell carcinoma of the bladder.
Requirements:
- Male or female age 22 or older
- Diagnosis of non-muscle invasive bladder cancer (NMIBC) only
Compensation: $25
Prostate Cancer Management
Sponsor: Ortho Clinical Diagnostics
Summary: A series of 3 blood draws over three months to collect data to substantiate the use of the VITROS Total PSA III test as an aid in management of prostate cancer.
Requirements:
- Men diagnosed with prostate cancer
Compensation: $25